Fed. Circ. Hears Teva Challenge To J&J Schizophrenia Drug

By Ryan Davis ( April 14, 2025, 8:33 PM EDT) — A Federal Circuit panel on Monday grappled with how to determine whether a dosage patent on Johnson & Johnson’s blockbuster schizophrenia drug Invega Sustenna is invalid as obvious, questioning attorneys for the company and generics maker Teva about the proper analysis….

SEO Powered Content & PR Distribution. Get Amplified Today.
PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
Source: https://www.law360.com/ip/articles/2322752?utm_source=rss&utm_medium=rss&utm_campaign=section

Generative Data Intelligence

Fed. Circ. Hears Teva Challenge To J&J Schizophrenia Drug